Nuvelution Pharma Enters Collaborative Risk-Sharing Agreement With Amgen
San Francisco, CA, March 30, 2018 – Nuvelution Pharma, Inc. today announced a collaborative risksharing agreement with Amgen. The collaboration has the objective of bringing a new treatment option to patients through a risk-sharing framework. Under the agreement, Nuvelution will earn a pre-agreed financial return on its investment upon product approval. Additional terms are not being disclosed.
“We are pleased to enter into this agreement with Amgen,” said Sandy Zweifach, President and CEO of Nuvelution Pharma. Inc. "We are confident that this development program will result in a successful conclusion for the benefit of patients in need.”
Collaborative development agreements are becoming an established mechanism within the pharmaceutical industry for late-stage drug development funding. They allow for shared risk and return models to be explored in a way that can maximize the development of a pipeline. They offer the potential to alter development productivity through a combination of reduced risk, increased availability of funding and operational resources, and known levels of return on investment.
About Nuvelution Pharma
Nuvelution leverages its extensive knowledge, experience and relationships in the pharma and biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market. For more information, please visit www.nvtpharma.com.
Contacts Nuvelution Pharma, Inc. Sandy Zweifach, 650-866-8065